Saturday 17 October 2026
Export XENE’s income statement to Excel — free account
Xenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022. In the quarter to June 2026, revenue grew 100.7%, EPS fell 3.74% and free cash flow fell 48.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
33.55
0.78
−2.27%
Follow XENE
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 1 | — | — | — | 3 | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
P/S ratio |
67.45 | 166.55 | — | 47.84 | 16.52 | 73.92 | 171.27 | — | — | 209.76 |
Altman Z-Score |
16.92 | (3.53) | — | 1.21 | 16.50 | 37.06 | 43.34 | — | — | 37.76 |
Altman Z″-Score (non-manufacturers) |
15.38 | (7.50) | — | (1.22) | 9.97 | 29.56 | 24.99 | — | — | 6.89 |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Beneish M-Score |
(0.58) | 5.34 | — | — | 1.94 | (1.63) | 1.12 | — | — | — |
P/Operating CF |
(26.04) | (7.57) | — | 17.19 | (40.51) | (65.81) | (68.92) | — | — | (43.59) |
P/B ratio |
1.90 | 1.44 | — | 4.04 | 3.25 | 2.51 | 3.13 | — | — | 6.11 |
Price to Tangible BV |
1.90 | 1.44 | — | 4.04 | 3.25 | 2.51 | 3.13 | — | — | 6.11 |
EV/Sales |
31.88 | 48.02 | — | 30.14 | 11.84 | 45.44 | 128.33 | — | — | 178.92 |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
EV/Operating CF |
(2.94) | (0.52) | — | (45.45) | (7.91) | (12.05) | (17.17) | — | — | (10.85) |
EV/FCF |
(2.90) | (0.51) | — | (35.98) | (7.50) | (11.71) | (16.68) | — | — | (10.82) |
Quick Ratio |
17.94 | 10.80 | 29.00 | 3.28 | 12.10 | 38.72 | 26.12 | 23.43 | 17.66 | 13.17 |
Current Ratio |
18.31 | 10.98 | 29.46 | 3.34 | 12.30 | 39.03 | 26.44 | 23.65 | 17.85 | 13.42 |
Net Debt/EBITDA |
2.68 | 1.16 | 2.81 | 3.01 | 5.81 | 7.07 | 4.64 | 3.01 | 2.27 | 1.48 |
Debt/Assets |
0.00% | 14.75% | 12.26% | 10.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.19 | 0.15 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.03 | 0.01 | 0.00 | 0.05 | 0.19 | 0.05 | 0.01 | 0.00 | 0.00 | 0.01 |
Operating CF/Net income |
0.85 | 0.94 | 1.10 | 0.12 | 1.72 | 0.90 | 0.79 | 0.83 | 0.77 | 0.81 |
Capex/Depreciation |
(0.32) | (0.48) | (0.58) | (1.30) | (3.07) | (2.26) | (1.78) | (2.73) | (1.20) | (0.31) |
Interest Coverage |
(49.24) | (68.29) | (27.29) | (29.86) | (64.67) | (169.51) | (14.82) | — | — | — |
| (36.81%) | (61.51%) | (48.09%) | (44.52%) | (22.60%) | (21.84%) | (19.77%) | (22.12%) | (27.85%) | (51.76%) | |
| (34.99%) | (54.05%) | (37.52%) | (29.64%) | (16.63%) | (20.25%) | (18.84%) | (21.22%) | (26.58%) | (48.34%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (62.37%) | (46.16%) | (136.38%) | (709.28%) |
Return on Tangible Assets |
(36.22%) | (73.44%) | (26.75%) | (38.81%) | (16.42%) | (14.04%) | (21.39%) | (29.07%) | (38.42%) | (65.57%) |
Average Days of Receivables |
40.49 | 514.05 | 0.00 | 43.45 | 20.67 | 54.74 | 38.15 | 0.00 | 0.00 | 66.72 |
Research and Development Expense of Revenue |
1,099.72% | 8,222.83% | 0.00% | 568.82% | 157.07% | 409.30% | 1,121.13% | 0.00% | 0.00% | 4,012.51% |
Selling, General and Administrative Expense of Revenue |
376.71% | 2,351.45% | 0.00% | 158.19% | 40.24% | 119.15% | 347.78% | 0.00% | 0.00% | 1,061.76% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
119.86% | 718.97% | 0.00% | 42.82% | 17.65% | 54.33% | 215.98% | 0.00% | 0.00% | 716.09% |
Graham Net Nets |
0.51 | 0.67 | — | 0.26 | 0.31 | 0.39 | 0.25 | — | — | 0.14 |
Graham Number |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Earnings Yield |
(18.85%) | (59.38%) | — | (11.75%) | (5.30%) | (5.95%) | (5.48%) | — | — | (9.73%) |
Free Cash Flow Yield |
(16.32%) | (56.07%) | — | (1.75%) | (9.55%) | (5.25%) | (4.49%) | — | — | (7.88%) |
Revenue per Share |
0.12 | 0.02 | 0.00 | 0.26 | 0.93 | 0.42 | 0.16 | 0.00 | 0.00 | 0.09 |
Operating CF per Share |
(1.26) | (1.60) | (1.79) | (0.18) | (1.39) | (1.59) | (1.63) | (2.26) | (2.33) | (3.52) |
Capex per Share |
(0.02) | (0.02) | (0.03) | (0.05) | (0.08) | (0.05) | (0.05) | (0.08) | (0.04) | (0.01) |
Free Cash Flow per Share |
(1.28) | (1.61) | (1.81) | (0.23) | (1.47) | (1.64) | (1.67) | (2.34) | (2.37) | (3.53) |
Cash per Share |
4.14 | 2.43 | 6.14 | 5.45 | 5.12 | 12.65 | 9.78 | 9.54 | 8.05 | 6.93 |
Shareholders Equity per Share |
4.12 | 2.00 | 5.32 | 3.55 | 4.96 | 12.61 | 11.92 | 13.87 | 9.69 | 7.34 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.12 | 2.00 | 5.32 | 3.55 | 4.96 | 12.61 | 11.92 | 13.87 | 9.69 | 7.34 |
Free Cash Flow |
(19.85) | (29.04) | (35.23) | (5.95) | (50.76) | (71.55) | (101.32) | (156.73) | (184.46) | (279.92) |
Working Capital |
62.09 | 40.74 | 117.21 | 101.49 | 167.00 | 544.70 | 577.60 | 617.69 | 599.67 | 518.86 |
Capital Expenditures |
(0.28) | (0.31) | (0.51) | (1.24) | (2.64) | (2.05) | (2.89) | (5.62) | (3.07) | (0.80) |
Net Current Asset Value |
62.09 | 34.63 | 102.20 | 89.15 | 163.95 | 537.05 | 567.65 | 608.09 | 592.03 | 509.25 |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Capex to Sales |
0.15 | 1.01 | 0.00 | 0.18 | 0.08 | 0.11 | 0.31 | 0.00 | 0.00 | 0.11 |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.62 | 0.62 | 0.88 | 0.57 | 0.24 | 0.20 | 0.25 | 0.21 | 0.25 | 0.29 |
Cash ROIC |
(15.50%) | (33.61%) | (14.83%) | (2.39%) | (14.57%) | (6.49%) | (7.71%) | (10.01%) | (13.35%) | (24.76%) |
Accounts Receivable Turnover |
7.00 | 0.97 | 0.00 | 14.17 | 24.41 | 8.04 | 5.03 | 0.00 | 0.00 | 5.28 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | — | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | — | — | — | — | — | — | — |
Average Receivables |
0.26 | 0.32 | 0.29 | 0.48 | 1.32 | 2.29 | 1.88 | 0.93 | 1.17 | 1.42 |
Average Payables |
3.11 | 3.48 | 3.75 | 6.47 | 9.85 | 12.30 | 17.97 | 24.09 | 30.10 | 37.24 |
Average Assets |
65.72 | 56.80 | 84.27 | 135.06 | 168.44 | 380.60 | 663.08 | 859.47 | 881.47 | 715.65 |
Average Common Equity |
62.47 | 49.92 | 65.75 | 89.90 | 123.93 | 352.96 | 631.90 | 824.71 | 841.41 | 668.33 |
Columns are period end dates